m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0034)
Name
Adriamycin
Synonyms
25316-40-9; Doxorubicin HCl; Adriacin; ADRIAMYCIN HYDROCHLORIDE; Hydroxydaunorubicin hydrochloride; Doxorubicin (Adriamycin) HCl; UNII-82F2G7BL4E; ADRIAMYCIN, HYDROCHLORIDE; KW-125; Lipodox; MLS001401460; 82F2G7BL4E; SMR000058570; CPD000058570; DSSTox_RID_78854; DSSTox_RID_80678; DSSTox_CID_10636; DSSTox_GSID_30636; DSSTox_GSID_45111; CCRIS 740; CAS-NOCAS_45111
    Click to Show/Hide
Status Phase 3 [1]
Structure
3D MOL
2D MOL
Formula
C27H30ClNO11
InChI
InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1
InChIKey
MWWSFMDVAYGXBV-RUELKSSGSA-N
PubChem CID
443939
TTD Drug ID
D0F4KU
DrugBank ID
DB00997
Full List of m6A Targets Related to This Drug
Rho GTPase activating protein 5 (ARHGAP5)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary ARHGAP5-AS1 also stabilized ARHGAP5 mRNA in the cytoplasm by recruiting METTL3 to stimulate m6A modification of Rho GTPase activating protein 5 (ARHGAP5) mRNA. As a result, ARHGAP5 was upregulated to promote chemoresistance and its upregulation was also associated with poor prognosis in gastric cancer. downregulation of ARHGAP5-AS1 in resistant cells evidently reversed the resistance to chemotherapeutic drugs including cisplatin (DDP), ADM, and 5-FU.
Responsed Disease Gastric cancer ICD-11: 2B72
 Disease Info 
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response Autophagy hsa04140
Cell Process Cellular processes
Cellular transport, Cellular catabolism
In-vitro Model BGC-823 Gastric carcinoma Homo sapiens CVCL_3360
SGC-7901 Gastric carcinoma Homo sapiens CVCL_0520
References
Ref 1 ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
Ref 2 Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer. Cell Death Dis. 2019 May 16;10(6):383. doi: 10.1038/s41419-019-1585-2.